Schlemm's canal drug eluting device and method

Abstract

A method of delivering a pharmaceutical composition to Schlemm's canal of an eye is disclosed. The method may include inserting a drug delivery device into Schlemm's canal along with a microstent. The drug delivery device may include a biodegradable polymer and a pharmaceutical composition, and the drug delivery device may be configured to erode over time and dissolve the pharmaceutical composition into the aqueous humor in Schlemm's canal as it erodes.

Description

[Technical field]

[0001] Incorporation by Reference All publications and patent applications mentioned in this specification are herein incorporated by reference in their entirety to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

[0002] The present invention, as set forth in the accompanying claims, relates generally to surgical implants such as ophthalmic devices, including, without limitation, ophthalmic drug delivery devices. [Background technology]

[0003] Glaucoma is an eye disease that causes a potentially harmful increase in intraocular pressure. Glaucoma drug therapy is often indicated to reduce aqueous humor production in an effort to lower intraocular pressure. Glaucoma surgery redirects the aqueous humor outflow from the anterior chamber through the trabecular meshwork to Schlemm's canal, where it then leaves the eye via outflow channels and episcleral veins. In addition, while there are drugs that can widen outflow channels and / or episcleral veins, there is currently no effective method to deliver these drugs at sufficient concentrations for sufficient time to sufficiently widen outflow channels and / or episcleral veins to lower intraocular pressure. Summary of the Invention [Means for solving the problem]

[0004]

[0005] Novel and useful systems, devices, and methods for ophthalmic surgery are set forth in the appended claims. Exemplary embodiments are provided to enable one of ordinary skill in the art to make and use the claimed subject matter.

[0005] For example, some embodiments may include a method of delivering a pharmaceutical composition to Schlemm's canal of an eye. The method may include inserting a drug delivery device into Schlemm's canal, inserting a microstent into Schlemm's canal that includes an open central channel that is partially widened by one or more wall supports, supporting a longitudinal portion of Schlemm's canal with the microstent, and allowing the drug delivery device to erode over time. The drug delivery device may include a biodegradable polymer and a pharmaceutical composition, and the drug delivery device may erode over time and elute the pharmaceutical composition into the aqueous humor in Schlemm's canal as it erodes. The method may further include widening one or more outflow channels and episcleral veins with the pharmaceutical composition.

[0006] Features, elements, and aspects described in connection with some embodiments can also be omitted, combined, or replaced with alternative features. Other features, objects, advantages, and preferred modes of making and using the claimed subject matter are described in more detail below with reference to the accompanying drawings of exemplary embodiments.

[0007] The novel features of the invention are set forth with particularity in the appended claims. The features and advantages of the present invention will be better understood by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which: [Brief description of the drawings]

[0008] [Figure 1] 1 shows a drug delivery device according to the present invention within Schlemm's canal near a microstent. [Diagram 2] 2 illustrates the drug delivery device of FIG. 1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] Drugs that widen the outflow channels and episcleral veins downstream of Schlemm's canal can help lower intraocular pressure. The flow of aqueous humor from the anterior chamber through Schlemm's canal can be enhanced by the use of Schlemm's canal microstents, as described in U.S. Patent Nos. 7,740,604, 8,337,509, 8,425,449, and 8,512,404. One aspect of the present invention is the combination of a Schlemm's canal microstent and a time-release drug delivery device arranged in Schlemm's canal downstream of the microstent to more effectively deliver drugs to the outflow channels and episcleral veins over a prolonged period of time.

[0010] 1 shows an exemplary ophthalmic microstent 400 with its body portion 404 disposed within Schlemm's canal 484 and its inlet 450 disposed within the anterior chamber 480. As shown, the body of the microstent 400 has a pair of struts 420, an opening 430, a spine area 424, and an open channel 434 extending along the body portion and having an open side facing the outflow channel. The microstent 400 may be inserted from the anterior chamber 480 through an opening 483 in the trabecular meshwork 482 and into Schlemm's canal 484 such that the inlet portion 450 resides within the anterior chamber 480. When placed within Schlemm's canal, the microstent 400 supports the walls of Schlemm's canal so that aqueous humor can flow from the anterior chamber 480 through the channel 476 in the ostium 450 and / or through the trabecular meshwork 482 and opening 430, into the opening channel 434 in the microstent body, and then into the collection channel 486 that leads to an episcleral vein (not shown). In some embodiments, the microstent 400 supports a longitudinal length of Schlemm's canal of at least 4 mm, a longitudinal length of Schlemm's canal of at least 6 mm, or a longitudinal length of Schlemm's canal of at least 8 mm. The microstent 400 may be, for example, one of the implants disclosed in U.S. Patent Nos. 7,740,604, 8,337,509, 8,425,449, 8,512,404, all of which are incorporated by reference in their entirety, or any other suitable Schlemm's canal microstent. The microstent 400 may be fabricated from one or more biocompatible materials that possess the necessary structural and mechanical attributes. Both metallic and non-metallic materials may be suitable. Examples of suitable metallic materials may include stainless steel, tantalum, gold, titanium, and a nickel-titanium alloy known in the art as Nitinol. For example, Nitinol is commercially available from Memry Technologies (Brookfield, CT), TiNi Alloy Company (San Leandro, CA), and Shape Memory Applications (Sunnyvale, CA).

[0011] FIG. 1 also shows a drug delivery device 500 arranged in Schlemm's canal near the microstent 400. As shown in FIG. 2, the drug delivery device 500 is formed from a biodegradable polymer 502, such as polylactic-co-glycolic acid (PLGA) or polyethylene glycol (PEG), or mixtures thereof. Additional suitable biodegradable or bioabsorbable polymers and copolymers may be derived from monomers such as glycolide, glycolic acid, lactide, lactic acid, caprolactone, dioxanone, trimethylene carbonate, and combinations thereof. In some cases, the biodegradable polymer 502 may additionally or alternatively include amorphous or semi-crystalline forms of such polymers. A drug to widen the collecting channels and episcleral veins is compounded with the biodegradable polymer of the drug delivery device to form pockets of drug 504 such that as the drug delivery device 500 biodegrades, the drug elutes into the aqueous humor flowing to the collecting channels. Suitable drugs include rho kinase inhibitors and K(ATP) channel blockers such as cromakalim.

[0012] In some embodiments, drug delivery device 500 is 7-10 mm in diameter and 6-8 mm long. In some embodiments, drug delivery device 500 is curved as shown in Figure 2 to conform to the curvature of Schlemm's canal. In other embodiments, drug delivery device 500 is flexible and conforms to the curvature of Schlemm's canal.

[0013] The drug delivery device 500 can be delivered into Schlemm's canal through the same opening in the trabecular meshwork used to place the microstent. In some embodiments, Schlemm's canal may be widened, such as by delivering a pressurized viscoelastic material into Schlemm's canal prior to placing the drug delivery device or microstent. For example, Schlemm's canal may be widened with a viscoelastic material by using the OMNI® Surgical System or by using one of the devices described in U.S. Patent Application No. 63 / 236,598.

[0014] In some embodiments, the drug delivery device 500 is placed close enough to the microstent (e.g., within 1-3 mm of the distal end of the microstent 400) so that it is within the aqueous humor flow from the microstent, so that the device 500 erodes and delivers the drug to the flowing aqueous humor. In some embodiments, the drug delivery device erodes and delivers the drug over an extended period of time, for example, over months or years.

[0015] When a feature or element is said herein to be "on" another feature or element, it can be directly on the other feature or element, or intervening features and / or elements may also be present. In contrast, when a feature or element is said to be "directly on" another feature or element, there are no intervening features or elements. It will also be understood that when a feature or element is said to be "connected," "attached," or "coupled" to another feature or element, it can be directly connected, attached, or coupled to the other feature or element, or intervening features or elements may be present. In contrast, when a feature or element is said to be "directly connected," "directly attached," or "directly coupled" to another feature or element, there are no intervening features or elements. Although described or illustrated with respect to one embodiment, features and elements so described or illustrated may be applicable to other embodiments. Those skilled in the art will also recognize that references to structures or features arranged "adjacent" to another feature may have portions that overlap or underlie the adjacent feature.

[0016] The terminology used herein is merely for the purpose of describing particular embodiments and is not intended to limit the invention. For example, as used herein, the singular forms "a", "an" and "the" are intended to include the plural unless the context clearly indicates otherwise. It will be further understood that as used herein, the terms "comprise" and / or "comprising" specify the presence of the stated features, steps, operations, elements and / or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components and / or groups thereof. As used herein, the term "and / or" includes any and all combinations of one or more of the associated listed items and may be abbreviated as " / ".

[0017] Spatially relative terms such as "under," "below," "lower," "over," "upper," and the like may be used herein for ease of description to describe the relationship of one element or feature to another element or feature as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if the device in the figures were inverted, an element described as "under" or "beneath" the other element or feature would be oriented "over" the other element or feature. Thus, the exemplary term "under" can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or in other orientations) and the spatially relative descriptors used herein will be interpreted accordingly. Similarly, the terms "upper," "lower," "vertical," "horizontal," and the like are used herein for illustrative purposes only, unless expressly stated otherwise.

[0018] The terms "first" and "second" may be used herein to describe various features / elements (including steps), but these features / elements should not be limited by these terms unless the context dictates otherwise. These terms may be used to distinguish one feature / element from another. Thus, a first feature / element discussed below can be referred to as a second feature / element, and similarly, a second feature / element discussed below can be referred to as a first feature / element without departing from the teachings of the present invention.

[0019] Throughout this specification and the claims that follow, unless the context requires otherwise, the word "comprise" and variations such as "comprises" and "comprising" mean that various components can be utilized together in combination in methods and articles (e.g., apparatus and methods, including compositions and devices). For example, it will be understood that the term "comprising" implies the inclusion of any described elements or steps, but not the exclusion of any other elements or steps.

[0020] As used in this specification and claims, including those used in the examples, unless otherwise expressly stated, all numbers may be read as if preceded by the word "approximately" or "about", even if the term is not clearly stated. The phrase "approximately" or "about" may be used when describing a size and / or location to indicate that the stated value and / or location is within a reasonably expected range of values ​​and / or locations. For example, a numerical value may have a value of + / -0.1% of the stated value (or range of values), + / -1% of the stated value (or range of values), + / -2% of the stated value (or range of values), + / -5% of the stated value (or range of values), + / -10% of the stated value (or range of values), or other values. Any numerical value given herein should also be understood to include approximately or about that value, unless the context indicates otherwise. For example, if the value "10" is disclosed, then "approximately 10" is also disclosed. Any numerical range recited herein is intended to include all subranges subsumed therein. It is also to be understood that when a value is disclosed as being "less than or equal to" that value, "greater than or equal to" and possible ranges between the values ​​are also disclosed, as would be properly understood by one of ordinary skill in the art. For example, if a value "X" is disclosed, "less than or equal to X" as well as "greater than or equal to X" (e.g., where X is a number) are also disclosed. It is also to be understood that throughout this application, data is provided in a number of different formats, and that this data represents endpoints and starting points, as well as ranges for any combination of the data points. For example, if a specific data point "10" and a specific data point "15" are disclosed, it is to be understood that greater than 10 and 15, greater than or equal to 10 and 15, less than 10 and 15, less than or equal to 10 and 15, and equal to 10 and 15 are considered to be disclosed, as well as between 10 and 15. It is also to be understood that each value between two specific values ​​is also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

[0021] Although various exemplary embodiments have been described above, any number of modifications may be made to the various embodiments without departing from the scope of the invention, as set forth by the claims. For example, the order in which the various described method steps are performed may often be changed in alternative embodiments, and in other alternative embodiments, one or more method steps may be omitted altogether. Optional features of the various device and system embodiments may be included in some embodiments and not included in other embodiments. Thus, the foregoing description has been provided primarily for illustrative purposes and should not be construed as limiting the scope of the invention, as set forth in the claims.

[0022] The examples and figures contained herein are for illustrative purposes only and do not represent limitations to the specific embodiments in which the subject matter may be practiced. As described, other embodiments may be utilized and derived therefrom, such that structural and logical substitutions and changes may be made without departing from the scope of the present disclosure. Such embodiments of the subject matter of the present invention may be referred to individually or collectively by the term "invention" merely for convenience, and are not intended to arbitrarily limit the scope of the present application to any single invention or inventive concept when a plurality is actually disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiment shown. The present disclosure is intended to cover any and all adaptations or variations of the various embodiments. Combinations of the above embodiments with other embodiments not specifically described herein will be apparent to those of skill in the art upon reviewing the above description.

Claims

1. 1. A system for drug delivery configured to deliver a pharmaceutical composition to Schlemm's canal of an eye, the system comprising: Microstents and a drug delivery device configured to be inserted into the Schlemm's canal, the drug delivery device comprising a biodegradable polymer and the pharmaceutical composition; the microstent is configured to be inserted into Schlemm's canal, the microstent including an open central channel partially enlarged by one or more wall supports, the microstent further configured to support at least a 4 mm longitudinal portion of Schlemm's canal with the microstent; The drug delivery device is further configured to erode over time, dissolving the pharmaceutical composition into the aqueous humor in the Schlemm's canal as it erodes, and widening one or more outflow channels and episcleral veins with the pharmaceutical composition.

2. The system described in claim 1, wherein the microstent is configured to be inserted from the anterior chamber of the eye through an opening in the trabecular meshwork, and the drug delivery device is configured to be inserted through the opening in the trabecular meshwork.

3. The system of claim 2 , wherein the drug delivery device is configured to be inserted into Schlemm's canal before the microstent is inserted into the canal.

4. The system of claim 2 , wherein the drug delivery device is configured to be inserted into Schlemm's canal after the microstent has been inserted into the canal.

5. The system described in claim 1, wherein the drug delivery device is configured to be placed within 3-6 mm of the microstent in Schlemm's canal.

6. 2. The system of claim 1, wherein the microstent includes an inlet portion and a main body portion, the open central channel and the one or more wall supports are arranged within the main body portion, the inlet portion includes an open channel that communicates with the open channel of the main body portion, and the microstent is configured to be inserted such that the main body portion is inserted into the Schlemm's canal from the anterior chamber of the eye and the inlet portion is positioned within the anterior chamber.

7. The system of claim 1 , wherein the microstent and the drug delivery device are inserted into Schlemm's canal after the canal is dilated.

8. The system described in claim 7, wherein a substance is injected into Schlemm's canal before the drug delivery device and the microstent are inserted into the Schlemm's canal.

9. The system of claim 8 , wherein the substance is a viscoelastic material.

Images